Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol

Sophelia H.S. Chan, Virginia C.N. Wong, Andrew G. Engel

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Congenital myasthenic syndrome caused by endplate acetylcholinesterase deficiency constitutes a rare autosomal recessive disease. We describe a child with early-onset ptosis, complete ophthalmoplegia, facial and proximal muscle weakness, easy fatigability, a decremental electromyographic response, and a repetitive compound muscle action potential not improved by anti- acetylcholinesterase medication. Mutation analysis of the collagenic tail of endplate acetylcholinesterase (COLQ) that encodes the collagenic structural subunit of acetylcholinesterase revealed two canonic splice-site mutations: a previously identified IVS15 + 1G>A mutation and a novel IVS2 - 1G>A mutation. Treatment with albuterol resulted in progressive improvement of muscle strength, exercise tolerance, and ophthalmoplegia. Further studies are needed of the efficacy of albuterol in different types of congenital myasthenic syndrome and the physiologic basis of its beneficial effects.

Original languageEnglish (US)
Pages (from-to)137-140
Number of pages4
JournalPediatric Neurology
Volume47
Issue number2
DOIs
StatePublished - Aug 1 2012

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol'. Together they form a unique fingerprint.

  • Cite this